Insider Transactions in Q3 2024 at Zenas Bio Pharma, Inc. (ZBIO)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 16
2024
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
801,624
+37.06%
|
-
|
|
Sep 16
2024
|
Enavate Sciences Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
882,353
+19.0%
|
$15,000,001
$17.0 P/Share
|
|
Sep 16
2024
|
Enavate Sciences Gp, LLC |
BUY
Conversion of derivative security
|
Indirect |
2,879,006
+50.0%
|
-
|
|
Sep 16
2024
|
Jason Raleigh Nunn |
BUY
Open market or private purchase
|
Indirect |
882,352
+23.46%
|
$14,999,984
$17.0 P/Share
|
|
Sep 16
2024
|
Jason Raleigh Nunn |
BUY
Conversion of derivative security
|
Indirect |
2,174,449
+50.0%
|
-
|
|
Sep 16
2024
|
Patrick G Enright Director |
BUY
Open market or private purchase
|
Indirect |
440,000
+36.23%
|
$7,480,000
$17.0 P/Share
|
|
Sep 16
2024
|
Patrick G Enright Director |
BUY
Conversion of derivative security
|
Indirect |
2,061,934
+45.58%
|
-
|
|
Sep 16
2024
|
Sr One Capital Management, LLC |
BUY
Open market or private purchase
|
Indirect |
2,235,294
+29.7%
|
$37,999,998
$17.0 P/Share
|
|
Sep 16
2024
|
Sr One Capital Management, LLC |
BUY
Conversion of derivative security
|
Indirect |
2,676,245
+50.0%
|
-
|
|
Sep 16
2024
|
Fairmount Funds Management LLC Director |
BUY
Open market or private purchase
|
Indirect |
300,000
+15.75%
|
$5,100,000
$17.0 P/Share
|
|
Sep 16
2024
|
Fairmount Funds Management LLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,304,891
+39.1%
|
-
|
|
Sep 16
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
156,635
+36.78%
|
-
|
|
Sep 16
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
536,540
+45.47%
|
-
|
|
Sep 13
2024
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Indirect |
58,823
+50.0%
|
$999,991
$17.0 P/Share
|